Alzex Neuropharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007
Period Ending	Dec '11 Dec 31, 2011	Dec '10 Dec 31, 2010	Dec '09 Dec 31, 2009	Dec '08 Dec 31, 2008	Dec '07 Dec 31, 2007
Net Income	0.03	0.08	-0.33	0.22	-0.36
Depreciation & Amortization	0.06	0.07	0.01	0.03	0.01
Other Amortization	-	-	0.06	-	-
Provision & Write-off of Bad Debts	0.07	-	-	0.05	-
Other Operating Activities	-0.03	-	-	-0.24	-0.01
Change in Accounts Receivable	0.18	0.03	0.11	0.11	0.04
Change in Accounts Payable	-0	-0.02	0.08	0.01	-0.01
Change in Other Net Operating Assets	-0.02	-0.08	-0.18	0.18	1.66
Operating Cash Flow	0.29	0.07	-0.24	0.36	1.33
Operating Cash Flow Growth	297.97%	-	-	-73.03%	588.34%
Capital Expenditures	-	-	-	-0.01	-0
Cash Acquisitions	-	-	-	-	-1.43
Sale (Purchase) of Intangibles	-	-	-	-0.38	-0.05
Other Investing Activities	-	-	-	-	0.01
Investing Cash Flow	-	-	-	-0.39	-1.47
Long-Term Debt Issued	0.1	0.09	0.27	0.05	-
Long-Term Debt Repaid	-0.3	-0.07	-0.07	-0.08	-
Net Debt Issued (Repaid)	-0.21	0.02	0.2	-0.03	-
Issuance of Common Stock	-	-	-	-	0.11
Other Financing Activities	-0.02	-0.04	-	-	-
Financing Cash Flow	-0.23	-0.02	0.2	-0.03	0.11
Net Cash Flow	0.06	0.05	-0.04	-0.07	-0.04
Free Cash Flow	0.29	0.07	-0.24	0.34	1.32
Free Cash Flow Growth	297.97%	-	-	-74.08%	594.96%
Free Cash Flow Margin	6.05%	1.88%	-2.71%	2.29%	8.75%
Levered Free Cash Flow	0.2	0.21	-0.22	-0.34	-0.01
Unlevered Free Cash Flow	0.2	0.23	-0.18	-0.3	0.03
Change in Working Capital	0.15	-0.08	0.02	0.29	1.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.